Myelofibrosis - ruxolitinib - initial authority application form (PB172)

Use this form to apply for initial PBS-subsidised treatment with ruxolitinib for high risk and intermediate-2 risk or intermediate-1 risk myelofibrosis.

Page last updated: 28 March 2025.
QC 33721